Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739358 · ClinicalTrials.gov registry record · Phase 1
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
A Phase 1 study, sponsored by Criterium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04739358 is a Phase 1 study that was terminated before completion, run by Criterium. The registered enrollment target is 2 participants.
The verdict
NCT04739358, a Phase 1 study, was terminated before completion, sponsored by Criterium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer with central nervous system metastasis. In some patients, who have developed resistance to their tyrosine kinase inhibitors (TKIs), this study will look at how effective tepotinib is in combination with TKIs. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life.
Interventions
- DRUG Tepotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2023-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04739358
The ClinicalTrials.gov registry entry for NCT04739358 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Criterium, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tepotinib is the first listed.
NCT04739358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04739358 about?
NCT04739358 is a clinical study titled "CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC". This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer with central nervous system metastasis. In some patients, who have developed resistance to their tyrosine kinase inhibitors (TKIs), this study will look at how effective tepotinib is ...
What is the current status of trial NCT04739358?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-05-25. Estimated completion is 2023-06-23.
What interventions are being tested in trial NCT04739358?
The interventions under investigation include: Tepotinib (DRUG).
Who is sponsoring clinical trial NCT04739358?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.